Zydus Lifesciences Limited has launched the world's first biosimilar of Nivolumab in India under the brand name Tishtha, reinforcing the company's growing capability in advanced biologics and Immuno-Oncology. Tishtha will be available in 100 mg and 40 mg dosages priced at 28,950 and 13,950 respectively. The prices are approximately 1/4th of the reference drug.
This will improve affordability and reduce the overall treatment burden for patients. The two-strength portfolio enables oncologists to optimise dosing and minimise wastage - a key driver of treatment economics in immunotherapy. Access to modern treatment is determined by three critical factors: consistency, affordability, and reach.
Reliable availability of checkpoint inhibitors is essential for cancer patients who require therapy over multiple cycles, as interruptions may add both clinical and financial stress for families. Developed and manufactured in India, Tishtha ensures long-term dependability for patients throughout their treatment journey. For patients living with cancer, sustained and predictable access to therapy is critical.
By introducing Tishtha in India, Tishtha in India, Zydus expands access to advanced Immuno-Oncology treatment.
